Ceva Santé Animale (Ceva) has announced the appointment of Brad McCol

McCollum succeeds Jean-Charles Tissot, who has been overseeing this region since 2019 and will now lead the global autogenous vaccines’ activities. Brad McCollum will lead Ceva’s business development and activities in the United States and Canada.

A graduate of the University of Oklahoma, Brad McCollum brings an impressive 25-year career in pharmaceuticals and animal health. Before joining Ceva, he served as senior vice president of petcare for the U.S. at Zoetis. His extensive leadership experience also includes different roles at Zoetis and over a decade at Pfizer.

McCollum looks forward to building on Ceva’s current successes across all species and accelerating growth in the companion animal sector. He is committed to delivering efficient solutions that meet customers’ evolving needs in the U.S. and Canada.

Brad McCollum states, “I am excited to assume the leadership of North America, committed to building on the strong legacy of providing customer value across all species. Leveraging my in-depth knowledge of the market and customer needs in North America, I am eager to continue innovating and offering novel solutions for our customers.”

Ceva, a global leader in the animal health industry, underlines its dedication to expanding its footprint in the U.S. market, with a particular emphasis on the veterinary channel, to successfully attain this objective.

Andras Bolcskei, executive vice president for global commercial operations at Ceva underscores the company’s ambition in the pet segment: “We are determined to play in the top league in the pet market, and Brad McCollum’s appointment reinforces our commitment to innovation and efficiency to address the evolving needs of our customers.”